glp-1 and graves disease Drugs Linked to Lower Risk of TED GLP-1 medications and thyroid disease

Lancet 2024;404(10467):20772093

By 2026, it's no longer a niche topic whispered about in clinical circles

However, it is difficult to discern whether these differences between studies are due to real differences between the molecules in terms of their cardiovascular effects

In another nationwide cohort study assessing the risk of depression in diabetic patients receiving GLP-1 agonists, Tsai et al 16 demonstrated evidence of a lower combined incidence of anxiety and/or depression in GLP-1 RA users than in nonusers

Serotonylation has first been shown in platelets, with serotonylation of GTPases by transglutaminases increasing the release of coagulation effectors that induce platelet aggregation [64]

Therefore, the utilization of GLP-1R medications in the treatment of AD may represent a promising approach